Cargando…
Octagam(®) for chronic inflammatory demyelinating polyneuropathy: results from three observational studies
AIM: To present data from three studies of a Post-Authorization Safety Surveillance (PASS) program for the subset of patients receiving Octagam(®) 5% or 10% for chronic inflammatory demyelinating polyneuropathy (CIDP). METHODS: Data on patients with CIDP treated with Octagam were analyzed to assess...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Future Medicine Ltd
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190209/ https://www.ncbi.nlm.nih.gov/pubmed/29517417 http://dx.doi.org/10.2217/nmt-2018-0006 |